NCT00570661View on ClinicalTrials.gov

Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 12, 2006

Primary Completion Date

August 25, 2008

Study Completion Date

June 10, 2013

Conditions
Active SystemicOnset Juvenile Idiopathic Arthritis
Interventions
DRUG

ITF2357

ITF2357 orally administered at the cumulative daily dose of 1.5 mg/kg, achieved by administration of different dose strengths identifiable by different colours.

Trial Locations (5)

18000

University Clinical Centre NisClinic of Paediatrics Department for Rheumatology Bul Dr Zoran Djindjica, Niš

6911000

Institute of Rheumatology Belgrade Resavska, Belgrade

022328

Clinica Institute Fundeni.Pediatric Clinic 258 Sos. Fundeni,, Bucharest

041451

"Clinical Emergency Children Hospital M.S. Curie Paediatric Clinic no. I 20 Ctin. Brancoveanu Bvd., 041451 Bucharest 4th district", Bucharest

6-811070

"Mother and Child Health Institute Dr. Vukan Cupic Clinic of Paediatrics Radoja Dakica", Belgrade

Sponsors

Lead Sponsor

Italfarmaco
All Listed Sponsors
lead

Italfarmaco

INDUSTRY

NCT00570661 - Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis | Biotech Hunter | Biotech Hunter